Accelerating Rare Disease Trial Recruitment
Overcoming the challenges of ultra-rare disease recruitment through global patient identification networks and innovative screening programs.
The Challenge
Ultra-rare diseases present unprecedented recruitment challenges due to extremely small patient populations scattered globally, often with fewer than 10,000 affected individuals worldwide. Traditional recruitment methods fail dramatically in this space, with patients frequently undiagnosed or misdiagnosed for years. Geographic dispersion means potential participants may be separated by continents, while complex genetic eligibility criteria require specialized testing capabilities. Language barriers, varying healthcare systems, regulatory differences across countries, and the urgent need for participants who may have limited life expectancy create a perfect storm of recruitment obstacles that have historically made rare disease trials nearly impossible to complete successfully.
Our Strategic Approach
Global Patient Identification Network
We established a comprehensive worldwide network spanning 45 countries, integrating rare disease registries, genetic testing laboratories, specialized medical centers, and patient advocacy organizations. Our platform connected over 200 rare disease clinics, 50+ genetic counseling centers, and 25 patient advocacy groups to create an unprecedented global reach for patient identification and engagement.
Advanced Genetic Screening Program
Developed a state-of-the-art genetic screening infrastructure that included whole exome sequencing, targeted gene panels, and copy number variant analysis. We partnered with leading genetic laboratories worldwide to provide free or subsidized genetic testing for potential participants, enabling precise molecular diagnosis and eligibility confirmation within days rather than months.
Comprehensive Travel & Support Services
Recognizing that patients might need to travel internationally for participation, we created a full-service travel coordination program including visa assistance, flight arrangements, accommodation booking, local transportation, medical escort services, and 24/7 multilingual support. We also established satellite sites in key regions to minimize travel burden.
Digital Patient Engagement Platform
Built a sophisticated digital ecosystem featuring multilingual patient portals, virtual consultations, remote consent processes, and telemedicine capabilities. The platform included educational resources, family support networks, and real-time communication tools to maintain engagement across time zones and language barriers throughout the trial duration.
Regulatory Harmonization Strategy
Developed streamlined regulatory pathways by working closely with FDA, EMA, and other international regulatory bodies to create harmonized protocols that could be rapidly approved across multiple jurisdictions. This approach reduced regulatory delays and enabled simultaneous trial initiation in key markets worldwide.
Remarkable Results
Faster enrollment through global coordination and genetic prescreening, reducing recruitment timeline from 36 months to 14 months for a target of 40 patients worldwide.
Countries successfully enrolled patients, representing the most geographically diverse rare disease trial in company history with participants from 6 continents.
Exceptional retention achieved through comprehensive support services, flexible visit scheduling, and dedicated patient advocacy coordinators throughout the study duration.
Key Takeaways
This pioneering approach to rare disease recruitment has fundamentally changed how the industry approaches ultra-rare patient populations. By creating a truly global infrastructure that prioritizes patient experience and removes traditional barriers to participation, we demonstrated that even the most challenging recruitment scenarios can be successfully navigated. The methodology developed for this trial has since been adopted as the gold standard for rare disease research, enabling breakthrough treatments to reach patients who previously had no hope for therapeutic intervention.